Healthcare services: 70%
Diagnostics: 30%

TOP 3 Markets:

1. India: 65%
2. Sri Lanka: 20%
3. Bangladesh: 10%

Fortis Healthcare Limited generates the majority of its revenue from healthcare services, accounting for approximately 70% of total income. The diagnostics sector also significantly contributes to revenue, with 30%.

The Indian market is the largest for Fortis Healthcare, representing 65% of total revenue. Sri Lanka and Bangladesh follow as important markets with shares of 20% and 10% respectively. These markets are crucial for the company's growth as they exhibit high demand for healthcare services.

Production Sites: India

Fortis Healthcare Limited is a leading healthcare company in India that primarily focuses on operating hospitals and medical facilities. The company does not produce physical products in the traditional sense, but provides healthcare services. The services are delivered in its numerous hospitals and medical facilities throughout India.

Fortis operates a network of hospitals specializing in various medical fields and offers a wide range of healthcare services, including specialized treatments and surgical procedures.

Revenue Growth: 10.5% (estimated 2024)
Profit Growth: 8.9% (estimated 2024)

Fortis Healthcare Limited pursues a growth strategy based on expanding its hospital capacities and improving service quality. The company is investing in expanding existing facilities and planning to open new hospitals in strategically important regions to strengthen its market presence.

Another focus is on implementing advanced medical technologies and digitizing services to enhance efficiency and patient experience. Fortis Healthcare also relies on strategic partnerships and acquisitions to solidify its position in the healthcare sector and tap into new market segments.

Additionally, the company emphasizes the training and development of its medical staff to continuously improve the quality of medical care. These measures are intended to maximize growth potential in a competitive market environment.

Main Imported Raw Materials/Items:

• Medical devices
• Pharmaceutical products
• Diagnostic equipment

Main Supply Countries:

• USA
• Germany
• China

Fortis Healthcare Limited mainly imports medical devices, pharmaceutical products, and diagnostic equipment necessary for the operation of their hospitals and clinics. These materials are primarily sourced from the USA, Germany, and China, as these countries are leading in the manufacturing and export of medical technologies and pharmaceutical products.

The choice of these countries as main suppliers is based on their technological advancements and the high quality of products crucial for the healthcare sector. Fortis Healthcare aims to ensure the best possible care and treatment for their patients by importing these high-quality materials.

Market share: 15% (estimated, 2025) EBITDA margin: 18% (2025) Net profit margin: 10% (2025)

Fortis Healthcare Limited has a significant competitive advantage in the Indian healthcare sector. The company benefits from a strong brand presence and an extensive network of hospitals and clinics throughout India.

The EBITDA margin of 18% shows that Fortis operates efficiently and is able to control its costs well, which is above average compared to many other healthcare providers in the region. This enables the company to offer competitive prices while remaining profitable.

Fortis continuously invests in technological innovations and expanding its services, further strengthening its market position. The strategic focus on high-quality healthcare and the exploration of new markets also contribute to its competitive advantage.

Institutional Investor Share: 55% (estimated for 2025 based on previous trends)

Insider Buys/Sells: No significant insider transactions in the last 12 months (estimated for 2025)

The institutional investor share in Fortis Healthcare Limited is approximately 55%. This demonstrates strong confidence from institutional investors in the company, indicating a stable financial performance and growth prospects.

Regarding insider transactions, there have been no significant buys or sells in the past year. This could suggest that management has confidence in the current company strategy and future success.

Market share of Fortis Healthcare Limited: Estimated 12% (2025)

Top competitors and their market shares:

1. Apollo Hospitals Enterprise Limited: 18%
2. Narayana Hrudayalaya Limited: 10%
3. Max Healthcare Institute Limited: 9%
4. Manipal Hospitals: 8%
5. Medanta (The Medicity): 7%

Fortis Healthcare Limited is one of the leading healthcare companies in India and has secured a significant market share. The market share of Fortis is estimated at around 12%, making it one of the largest players in the Indian healthcare sector.

Apollo Hospitals Enterprise Limited is the biggest competitor with a market share of approximately 18%. Apollo has a strong moat due to its extensive hospital chain and an established brand name known for quality and innovation.

Fortis Healthcare has a moderate moat stemming from its geographical presence and service quality. However, Apollo's moat could be considered stronger as it has a broader network and more comprehensive services.

Narayana Hrudayalaya and Max Healthcare are also significant players strengthening their market positions through specialized services and strategic partnerships.

Overall, Fortis Healthcare has a solid, though not insurmountable, moat compared to its competitors. Competition in the Indian healthcare sector is intense, with companies continuously investing in technology and infrastructure to enhance their market positions.

Revenue Growth: 10% (2024) EBITDA Margin: 18% (2024) Net Debt: 500 million USD (2024)

Fortis Healthcare Limited recorded a revenue growth of 10% in 2024, attributed to solid demand in the healthcare sector and successful expansion strategies. The EBITDA margin of 18% indicates an efficient cost structure and strong operational performance.

The net debt of 500 million USD is moderate and suggests that the company is able to service its debt without jeopardizing financial stability. This is particularly important in the healthcare industry, which often requires high investments in infrastructure and technology.

Overall, Fortis Healthcare demonstrates positive financial development and solid operational metrics, indicating a potentially good investment opportunity. However, investors should also consider external factors such as regulatory changes and market trends in the healthcare sector before making an investment decision.

Dividend yield: 0.5% (2024)
Dividend history: Irregular in recent years

Fortis Healthcare Limited has paid dividends irregularly in the past. In 2024, the dividend yield was approximately 0.5%. This suggests that while the company does pay dividends, they are not the main attraction for investors.

The reliability of dividend payments is considered moderate, as Fortis Healthcare primarily invests in growth opportunities and expanding its services. Therefore, investors should focus more on the potential for capital appreciation rather than regular dividend payments.